 |
 |
|
Dr. Dagnall joined Behrman Capital in 2004. He has over 30 years of
professional experience in the preclinical sector of drug development
and is internationally recognized as an industry expert in
pharmaceutical outsourcing. Most recently he served as the President and
CEO of SkeleTech, Inc. a preclinical contract research organization
focused on testing bone and central nervous system drug candidates.
Previously, he served as the executive vice president and COO of Covance
Biotechnology Services. He has also been responsible for the technical
and administrative operations of laboratories at leading preclinical
contract research organizations including Corning Hazleton, Hazleton
America, and Huntingdon Research Centre. Dr. Dagnall holds a Ph.D. in
Analytical Chemistry from Birmingham University, U.K., and a Doctor of
Science in Analytical Chemistry from London University, U.K. Dr. Dagnall
currently serves as Chairman of the Board and Chief Executive Officer of
WIL Research Holding Company, Inc. |
|
| |
|
| |
©2008 Behrman Capital, All Rights
Reserved.
126 East 56th Street, New York, NY 10022 v. (212)
980-6500 f. (212) 980-7024
One Maritime Plaza, Suite 1555, San Francisco, CA
94111
v. (415) 434-7300 f. (415) 434-7310
|
|
